Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

July 7, 2025/in News/by edendesign

Abstract

GENEVA – (BUSINESS WIRE) – Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology, and its PBM device for the treatment of early and intermediate dry AMD.¹ LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.^2,* Dry AMD is a progressive disease typically treated in late stage, with limited treatment options.²

Read More on businesswire.com or download the PDF.

Latest News

The Pope, who was forced into a wheelchair was put on his feet with his therapy of Hungarian professorAugust 8, 2025 - 10:21 am
Abstract On the tenth anniversary of his election, Pope Francis recovered. Literally. He spent the last year in a wheelchair due to his severe knee problems, he was unable to walk because of his severe pain, he almost turned the thought of retiring in his head. But then he was cured by the therapy of […]
LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery SystemAugust 7, 2025 - 4:03 pm
Abstract Purpose: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System. Methods: LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were given multiwavelength PBM (590, 660, and 850 nm) or […]
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)July 7, 2025 - 11:37 am
Abstract GENEVA – (BUSINESS WIRE) – Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology, and its PBM device for the treatment of early and intermediate dry AMD.1 LumiThera’s PBM is the only device […]
Harnessing Medical Innovation to Make America Healthy AgainMay 1, 2025 - 11:39 am
Abstract Join The Heritage Foundation and leading medical scientists for a discussion of cutting edge medical technology and its wider implementation to make Americans healthier. Photobiomodulation (PBM) and hyperbaric oxygen therapy (HBOT) are two proven treatments that stimulate cell growth in patients suffering from a vast array of conditions. Managing pain, promoting wound healing, and […]
Photobiomodulation Clinic at Mass General Offers a Promising New Treatment for Neuropsychiatric DisordersFebruary 25, 2025 - 11:49 am
Abstract Transcranial photobiomodulation (PBM) is emerging as an innovative approach to treat various neuropsychiatric conditions, including major depressive disorder, generalized anxiety disorder, traumatic brain injury, and Alzheimer’s disease and other types of dementia. The Brain Photobiomodulation Clinic at Mass General Hospital, under the direction of Paolo Cassano, MD, PhD, offers this cutting-edge treatment for patients […]
Lighting the Way to a Healthier AmericaFebruary 14, 2025 - 11:53 am
Abstract The Make America Healthy Again (MAHA) movement is now national policy with Trump establishing the MAHA Commission and Robert F. Kennedy, Jr. as the Secretary of the Department of Health & Human Services (HHS). Americans are universally concerned about their health, but well-financed and entrenched interests are thwarting MAHA. Big Pharma spends $400 million […]
Local athletes to be subjects of new, international studyFebruary 5, 2025 - 10:37 am
Abstract SHEPHERDSTOWN — Athletes from Shepherd University will soon be some of the subjects of a new study being conducted by photobiomodulation (PBM) therapy researchers. According to Ann Liebert, who is the coordinator of photomolecular research at Sydney Adventist Hospital in Australia, the research will focus on whether or not PBM therapy heals concussions. […]
Military Explores Light Therapy for Brain InjuriesDecember 20, 2024 - 1:33 pm
Abstract The U.S. Department of Defense (DOD) is taking steps to explore how noninvasive, nondrug light therapy can help military members and veterans recover from traumatic brain injuries (TBI). Read More on heartlanddailynews.com or download the PDF
LumiThera Receives FDA Authorization for Valeda Treatment for Dry AMDNovember 5, 2024 - 10:33 am
Abstract The U.S. FDA has granted LumiThera authorization to market its Valeda Light Delivery System, the first FDA-authorized device designed to treat vision loss in patients with dry age-related macular degeneration (AMD). This significant approval, obtained through the De Novo authorization pathway, marks a major milestone in noninvasive treatments for dry AMD. Read More […]
Red Light Therapy: Benefits For Athletic Performance, Recovery, And Pain ReliefSeptember 25, 2024 - 4:31 pm
Abstract You’ve seen the celebrities and influencers donning futuristic LED face masks to improve signs of aging and acne. The technology behind it—red light therapy(RLT), which is a form of photobiomodulation, as scientists say—has potential perks that are more than skin-deep. Elite athletes, for example, hop into specialized red light beds to speed up recovery […]

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

PBM Basics

Education & Research

Who We Are

News & Events

Contact